Table 1. Body mass gain throughout the experimental period.

Body mass (g)
Females
	PN37	PN38	PN39	PN40	PN41	PN42	PN43	PN44	PN45	PN46	PN47	PN48	PN49	PN50	PN51	PN52	PN53
CT	16.2±0.3	16.2±0.2	16.4±0.2	16.5±0.2	16.7±0.3	16.9±0.3	16.9±0.2	17.0±0.3	17.1±0.3	17.2±0.3	17.2±0.3	17.3±0.3	17.5±0.3	17.6±0.3	17.6±0.3	17.7±0.3	17.7±0.2
NIC	16.5±0.3	16.7±0.4	17.0±0.5	17.2±0.6	16.9±0.4	17.3±0.4	17.2±0.4	17.4±0.4	17.2±0.4	17.4±0.4	17.5±0.4	17.6±0.4	18.1±0.4	18.0±0.4	18.0±0.4	18.2±0.4	18.2±0.4
PCP	16.2±0.4	16.2±0.3	16.5±0.3	16.4±0.3	16.5±0.3	16.6±0.3	16.6±0.3	16.7±0.3	16.8±0.3	16.8±0.3	16.9±0.3	17.0±0.3	17.3±0.4	17.3±0.3	17.3±0.3	17.4±0.3	17.4±0.3
PCP-NIC	16.7±0.3	16.5±0.3	16.5±0.3	16.9±0.3	17.1±0.3	17.3±0.3	17.4±0.2	17.5±0.3	17.6±0.3	17.7±0.3	17.8±0.3	18.0±0.3	18.1±0.3	18.2±0.3	18.3±0.3	18.4±0.3	18.4±0.3
Males
	PN37	PN38	PN39	PN40	PN41	PN42	PN43	PN44	PN45	PN46	PN47	PN48	PN49	PN50	PN51	PN52	PN53
CT	18.4±0.4	18.7±0.4	19.0±0.4	19.2±0.4	18.9±0.7	19.6±0.4	19.9±0.3	20.0±0.4	20.1±0.3	20.2±0.4	20.5±0.4	20.7±0.4	20.8±0.3	20.9±0.3	21.0±0.4	21.1±0.3	21.1±0.4
NIC	19.1±0.4	19.3±0.4	19.4±0.4	19.6±0.3	19.8±0.3	20.1±0.3	20.4±0.3	20.5±0.3	20.6±0.3	20.9±0.3	21.0±0.3	21.3±0.4	21.5±0.3	21.6±0.3	21.7±0.3	21.6±0.3	21.7±0.3
PCP	19.0±0.3	19.2±0.3	19.0±0.3	19.3±0.3	19.7±0.3	20.1±0.2	20.0±0.3	20.1±0.2	20.4±0.2	20.4±0.2	20.5±0.2	20.7±0.2	20.7±0.2	20.9±0.2	21.0±0.2	20.9±0.2	21.1±0.2
PCP-NIC	18.6±0.5	18.6±0.4	18.9±0.4	19.1±0.3	19.3±0.4	19.6±0.3	19.7±0.3	20.0±0.3	19.9±0.4	20.2±0.3	20.3±0.3	20.4±0.4	20.6±0.3	20.7±0.4	20.8±0.4	21.0±0.3	21.1±0.3

CT: Control group (♀ = 12, ♂ = 16); NIC: Nicotine-exposed group (♀ = 14, ♂ = 14); PCP: Phencyclidine-treated group (♀ = 14, ♂ = 14); PCP-NIC: Phencyclidine-treated and nicotine-exposed group (♀ = 12, ♂ = 14). PN: Postnatal day. Values are means ± SEM.